Open AccessPROSPECTS OF COMBINING INTERLEUKIN-2 WITH IMMUNE CHECKPOINT INHIBITORS FOR CANCER THERAPY
Author(s) -
Mikhail Kiselevskiy,
Irina O. Chikileva,
О В Жаркова,
Н В Зиганшина,
Lyubov Korolenkova,
С. М. Ситдикова
Publication year - 2020
Publication title -
voprosy onkologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.108
H-Index - 11
eISSN - 2949-4915
pISSN - 0507-3758
DOI - 10.37469/0507-3758-2020-66-1-23-28
Subject(s) - medicine , immune system , clinical trial , cancer , immunotherapy , immune checkpoint , cytokine , immunology , interleukin , oncology
The review summarizes results of pre-clinical and clinical investigations of combination therapies with interleukin-2 and immune checkpoint inhibitors. It presents data of the current registered clinical trials of immune checkpoint combinations either with interleukin-2 or the cytokine-activated lymphocytes. The up-to-date experimental and preliminary clinical data evidence that such an immune therapy strategy is highly promising for cancer treatment.